Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

March 28, 2024

REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the company will deliver multiple presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held April 5-10, 2024, in San Diego, California.

Details of the planned presentations are listed below:

**Revolution Medicines Oral Presentations:**

**Title:** Discovery of RMC-9805, an Oral, RAS(ON) G12D-Selective Covalent Tri-Complex Inhibitor
**Presenter:** John Knox, Ph.D.
**Abstract Number:** ND03
**Session:** New Drugs on the Horizon: Part 1
**Date/Time:** 1:45 – 2:00 p.m. PT on April 7, 2024

**Title:** RMC-6236, a RAS(ON) Multi-Selective Tri-Complex Inhibitor
**Presenter:** Elena Koltun, Ph.D., Wei Lin, M.D.
**Session:** KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology
**Date/Time:** 1:00 – 1:20 p.m. PT on April 9, 2024

**Title:** Combination of RAS(ON) G12C-Selective and Multi-Selective Tri-Complex Inhibitors Overcomes Resistance and Prolongs Durability in Preclinical Models of KRASG12C NSCLC
**Presenter:** Xing Wei, Ph.D.
**Abstract Number:** 6585
**Session:** Novel Antitumor Agents 5
**Date/Time:** 2:35 – 2:50 p.m. PT on April 9, 2024

**Revolution Medicines Poster Presentations:**

**Title:** Potential Biomarkers of Response to the Combination of the RAS(ON) Multi-Selective Inhibitor RMC-6236 Plus Anti-PD-1 Antibody in Preclinical PDAC Models
**Presenter:** Lillian Seu, Ph.D.
**Abstract Number:** 581/4
**Session:** Immunotherapy
**Date/Time:** 1:30 – 5:00 p.m. PT on April 7, 2024

**Title:** RMC-5127, a First-in-Class, Orally Bioavailable RAS(ON) G12V-Selective Tri-Complex Inhibitor, is CNS-Penetrant and Drives Regressions in Intracranially Implanted KRASG12V Xenograft Tumors
**Presenter:** Zhe Chen, M.B.B.S., Ph.D.
**Abstract Number:** 3340/28
**Session:** Novel Antitumor Agents 3
**Date/Time:** 1:30 – 5:00 p.m. PT on April 8, 2024

**Title:** The RAS(ON) Multi-Selective Inhibitor RMC-7977 Blocks Downstream MAPK and PI3K Pathway Activation in KRASG12X-Mutant Cancers
**Presenter:** Priyanka Bapat, Ph.D.
**Abstract Number:** 4709/2
**Session:** Other Cellular Mechanisms for Anticancer Drug Action
**Date/Time:** 9:00 a.m. – 12:30 p.m. PT on April 9, 2024

**Collaborator Poster Presentations:**

**Title:** RTK Signaling and WT RAS Activity as Vulnerabilities in Tumors with Acquired Resistance to GDP-State Selective KRASG12C Inhibitors in Preclinical Models
**Lead RevMed Co-Author:** Harshit Shah, Ph.D.
**Abstract Number:** 1924/2
**Session:** Drug Resistance 2: RAS GTPase
**Date/Time:** 9:00 a.m. – 12:30 p.m. PT on April 8, 2024
Title: Resistance to RAS-GTP Inhibition in Models of Pancreatic Ductal Adenocarcinoma Arises Downstream of RAS Effectors

Lead RevMed Co-Author: Jingjing Jiang, Ph.D.
Abstract Number: 1927/5
Session: Drug Resistance 2: RAS GTPase
Date/Time: 9:00 a.m. – 12:30 p.m. PT on April 8, 2024

About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).

Media & Investor Contact Erin Graves 650-779-0136 egraves@revmed.com